Copper serves as an essential cofactor for enzymes involved in a multitude of physiological processes such as mitochondrial respiration, iron metabolism, neuropeptide biogenesis, and connective tissue formation. An appropriate copper content is critical for normal growth and development, and inappropriate Cu levels have been associated with pathological conditions such as neurodegeneration, cancer, and immune disorders. The high‐affinity copper transporter Ctr1 is an evolutionarily conserved copper importer that plays a crucial role in dietary copper uptake and intracellular copper distribution. Additionally, Ctr1 has been implicated in cellular uptake of platinum‐based chemotherapeutic agents. As the primary Cu importer, Ctr1 is a promising therapeutic target of numerous diseases associated with inappropriate Cu levels. Recent advances in structural and mechanistic studies of Ctr1, including electron and X‐ray crystallographic analyses and functional reconstitution, have provided insights into copper transport mechanisms, suggesting novel therapeutic opportunities for the treatment of Cu metabolism diseases.